Latest Vascular endothelial growth factor Stories
Study Did Not Meet Primary or Key Secondary Endpoints SAN DIEGO, May 20, 2015 /PRNewswire/ -- Lpath, Inc.
LONDON, May 13, 2015 /PRNewswire/ -- Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Hutchison MediPharma Limited ("HMP"), its majority owned
Breakthrough eyedrop therapeutic to treat Diabetic Retinopathy. Oklahoma City, OK and Seattle, WA (PRWEB) May 04, 2015 EyeCRO LLC and NeuMedics Inc.,
CYRAMZA Now Approved in the U.S.
CRANBURY, N.J., April 15, 2015 /PRNewswire/ -- Oncobiologics, Inc., a biotherapeutics company focused on developing and commercializing biosimilars, today announced that clinical development
LONDON, April 6, 2015 /PRNewswire/ -- Report DetailsAnalysis of revenues and R&D prospects for those eye drugs - you explore potentialsWhat's the future for treating disorders
Efficacy and Safety of Long-term, Continuous Anti-VEGF will be Assessed in Phase 2 Study CUMBERLAND, R.I., March 30, 2015 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc.
Market Publishers Ltd informs that new reports by GlobalData have been recently uploaded to its catalogue. London, UK (PRWEB) March 25, 2015 Market Publishers
Diabetic retinopathy in patients with DME is the fourth approved indication for EYLEA in the U.S. TARRYTOWN, N.Y., March 25, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
DALLAS, March 19, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Lucentis (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023" market research
- To say in too many words; to express verbosely.
- To express in too many words: sometimes used reflexively.
- The leading idea or a repeated phrase, as of a song or ballad; the refrain; burden.